Bacterial Infection Clinical Trial
Official title:
A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
This is a randomized, multi-center, double-blind study to evaluate the efficacy and safety of
three regimens of brilacidin compared to an active control, daptomycin, in subjects with
ABSSSI. Subjects must have infections that warrant intravenous therapy but may be treated as
either inpatients or outpatients.
Eligible subjects will be randomized to one of 4 treatment groups in a 1:1:1:1 ratio.
Subjects randomized to brilacidin will receive either a single intravenous infusion (0.6
mg/kg or 0.8 mg/kg) followed by six days of once daily placebo, or a three day regimen (0.6
mg/kg on Day 1 followed by 0.3 mg/kg on Days 2 and 3) followed by 4 days of once daily
placebo. Subjects randomized to daptomycin will receive 7 days of treatment. Subjects will be
assessed for both clinical and microbiologic efficacy 48-72 hours after the first dose of
study drug. After an assessment at Day 7-8, subjects will be again be evaluated for efficacy
at Day 10-14 and via a phone contact at Day 21-28.
Approximately 200 subjects randomized in a 1:1:1:1 ratio to receive one of the three
brilacidin regimens or daptomycin will be evaluable. The primary efficacy outcome, early
clinical response 48-72 hours after the first dose of study drug, will be determined in the
Intent-to treat (ITT) population. Additional efficacy and safety analyses will be performed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02794831 -
Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections
|
||
| Active, not recruiting |
NCT02533609 -
Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
|
||
| Completed |
NCT01892358 -
Preventing Bacterial and Viral Infections Among Injection Drug Users
|
N/A | |
| Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
| Completed |
NCT01446289 -
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
|
Phase 2 | |
| Completed |
NCT01059890 -
Cerebral Antibiotics Distribution After Acute Brain Injury
|
Phase 1 | |
| Completed |
NCT00389558 -
Antiseptic Use and Dressing Application
|
Phase 4 | |
| Completed |
NCT00760279 -
An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates
|
Phase 1 | |
| Completed |
NCT02311816 -
Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients
|
N/A | |
| Completed |
NCT01225042 -
The Effect of Probiotics on E. Coli Gastroenteritis
|
N/A | |
| Not yet recruiting |
NCT00765778 -
Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community
|
N/A | |
| Completed |
NCT00915213 -
Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy
|
N/A | |
| Completed |
NCT00800488 -
Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months
|
N/A | |
| Terminated |
NCT00307099 -
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
|
Phase 3 | |
| Recruiting |
NCT04479657 -
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
|
Early Phase 1 | |
| Completed |
NCT03299894 -
Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department
|
N/A | |
| Completed |
NCT01817075 -
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT01250574 -
Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
|
||
| Completed |
NCT01244698 -
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
|
Phase 4 | |
| Completed |
NCT01012089 -
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
|
N/A |